The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- Why Shares of Sarepta Therapeutics Skyrocketed Today
- Why I'm Buying Sarepta Therapeutics Stock
- What Is an Abbreviated New Drug Application, And What Does It Mean to Investors?
- Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity
- Investors Just Doubled Their Money on This Stock
- There's More to This Company Than Marijuana